In a genome-wide CRISPR/Csa9 screen project aimed to identify synthetic vulnerabilities to BCL-2 inhibition in AML, sgRNAs targeting CLPB were found to sensitize AML blasts to venetoclax [36]. This evidence concerns the gene CLPB and acute myeloid leukemia.